Hereditary breast cancer

Hereditary breast cancer (also known as familial breast cancer or hereditary breast and ovarian cancer syndrome when associated with BRCA mutations) is a form of breast cancer caused by inherited pathogenic variants in cancer predisposition genes, most commonly BRCA1 and BRCA2. Other genes associated with hereditary breast cancer include TP53 (Li-Fraumeni syndrome), PALB2, CHEK2, ATM, CDH1, PTEN (Cowden syndrome), and STK11 (Peutz-Jeghers syndrome). Hereditary breast cancer accounts for approximately 5–10% of all breast cancer cases. Individuals carrying these pathogenic variants have a significantly elevated lifetime risk of developing breast cancer, often at younger ages than sporadic cases, and may also face increased risks for ovarian, pancreatic, prostate, and other cancers depending on the gene involved. The disease primarily affects the breast tissue, where malignant tumors develop in the ducts or lobules of the breast. Key clinical features that suggest a hereditary etiology include early age of onset (often before age 50), bilateral breast cancer, multiple affected family members across generations, male breast cancer, and the occurrence of associated cancers such as ovarian cancer in the same family. BRCA1-associated breast cancers are frequently triple-negative (estrogen receptor, progesterone receptor, and HER2 negative), which has implications for treatment selection. Management of hereditary breast cancer involves a combination of enhanced surveillance, risk-reducing strategies, and standard oncologic treatment. Enhanced surveillance includes earlier and more frequent mammography and breast MRI screening, often beginning at age 25–30. Risk-reducing options include prophylactic bilateral mastectomy and bilateral salpingo-oophorectomy, which substantially reduce cancer risk. Chemoprevention with selective estrogen receptor modulators (such as tamoxifen) or aromatase inhibitors may also be considered. For individuals who develop cancer, treatment follows standard oncologic protocols including surgery, chemotherapy, radiation therapy, hormonal therapy, and targeted therapies. Notably, PARP inhibitors (such as olaparib and talazoparib) have been approved specifically for BRCA-associated breast cancers, representing an important advance in precision medicine for this population. Genetic counseling and cascade testing of at-risk family members are essential components of care.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Hereditary breast cancer